BMB Reports 2018; 51(7): 327-337  https://doi.org/10.5483/BMBRep.2018.51.7.113
Laminopathies; Mutations on single gene and various human genetic diseases
So-mi Kang, Min-Ho Yoon, and Bum-Joon Park*
Department of Molecular Biology, College of Natural Science, Pusan National University, Busan 46241, Korea
Correspondence to: Tel: +82-51-510-2220; Fax: +82-51-513-9258; E-mail: bjpark1219@pusan.ac.kr
Received: April 25, 2018; Published online: July 31, 2018.
© Korean Society for Biochemistry and Molecular Biology. All rights reserved.

cc This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

Lamin A and its alternative splicing product Lamin C are the key intermediate filaments (IFs) of the inner nuclear membrane intermediate filament. Lamin A/C forms the inner nuclear mesh with Lamin B and works as a frame with a nuclear shape. In addition to supporting the function of nucleus, nuclear lamins perform important roles such as holding the nuclear pore complex and chromatin. However, mutations on the Lamin A or Lamin B related proteins induce various types of human genetic disorders and diseases including premature aging syndromes, muscular dystrophy, lipodystrophy and neuropathy. In this review, we briefly overview the relevance of genetic mutations of Lamin A, human disorders and laminopathies. We also discuss a mouse model for genetic diseases. Finally, we describe the current treatment for laminopathies.

Keywords: EDMD, HGPS, Lamin A, Laminopathy, Nuclear membrane
INTRODUCTION

The main character of eukaryotes is the presence of separated genome containing nucleus from cytoplasm (1). Although there are many merits to the existing nucleus acting as a separated organelle (stable maintenance of genomic material and alternative use of genetic material), the morphology of the nucleus needs to be maintained and the materials should be transported across the nuclear membrane, which is continuous with the Endoplasmic Reticulum (ER; 2). To maintain the nuclear morphology and ensure resilience, the intermediate filament mesh in the inner nuclear membrane and the nuclear plasm can also co-evolve with eukaryotic cells. The core components of the nuclear intermediate filaments (IFs) are Lamin A, Lamin C, and Lamin B (3). These proteins are conserved from yeast to mammalian cells (4). However, these proteins do not seem to be part of the simple physical network of the nuclear plasm. Lamin A/C forms a network and is associated with Emerin and the nuclear pore complex (5, 6). Emerin is a linker between the Lamin A/C mesh and the cytoplasmic actin filament (7). Thus, this interaction may involve the localization of the nucleus in all cells and nuclear movement when cells migrate (8) A more interesting feature is the absence of Lamin A/C expression in stem cells and neurons (9, 10); these types of cells only express Lamin B as a nuclear IF.

Due to the various functions of Lamin A/C, genetic mutations on Lamin A/C induce a broad range of human genetic diseases (so called laminopathies; 1114). The case of laminopathy is very unusual. In general, mutations on a single gene are involved in a single disease. For example, various types of genetic mutations on p53 are related to cancer or cancer-related pathogenesis (15). However, mutations on Lamin A/C can induce different diseases from premature aging to neuropathy.

In this paper, we discuss the physiological processing of Lamin A/C and the relevance of mutations and laminopathies. We also describe the recent treatment of laminopathies.

LAMIN A PROCESSING

The LMNA gene is located on chromosome 1q21.2 loci and is composed of 12 exons (Fig. 1; 16). Exons 1–10 between Lamin A and Lamin C are identical (Fig. 1) and exons 11 and 12 are specific to Lamin A. Lamin C is produced by unique exon 11, which is transcribed by alternative splicing and translated into only 6 amino acids (VSGSRR; 17). Exon 12 on Lamin A possesses a CaaX motif (actual amino acid sequence is CSIM), which is at the end of Lamin A and the farnesylated motif (18). Lamin A is first produced as prelamin A containing the CaaX motif and maturates by protease-mediated cleavage (17, 18). Thus, matured Lamin A does not have a farnesylated CaaX motif. Zmspte24 has been suggested as the responsible protease for Lamin A maturation (19). Loss of Zmste24 also induces laminopathies (lipodystrophy and dermopathy; 20, 21). Thus, the correct processing of Lamin A is also important for maintaining a healthy cellular condition. The biological function of C-terminal farnesylation would be targeting of Lamin A to nuclear membrane. However, considering that only mature Lamin A mouse expression is indistinguishable from wild type mouse (22), it is unclear why Lamin A is expressed as prelamin A. This implies that matured Lamin A does not work as an attached form of the nuclear membrane. In contrast, the binding of Lamin A (prelamin A) on the nuclear inner membrane may cause problems (laminopathies). The CaaX motif of Lamin B expressed differentially from Lamin A is not eliminated, and Lamin B is associated with the nuclear membrane (23). These results suggest that the primary nuclear IF is the Lamin B mesh. In fact, Lamin B is expressed in all types of cells, including stem cells and neurons. In addition, the rarity of laminopathies by Lamin B mutation also supports the possibility that Lamin B is a more essential IF than Lamin A.

LAMINOPATHIES AND MUTATIONS

As described previously, mutations on Lamin A or related proteins induce various types of human diseases. These diseases are divided into two large categories: primary laninopathies which are induced by mutations on Lamin A and secondary laminopathies which are caused by mutations on Lamin B (Lamin B1 and Lamin B2), prelamin processing proteins (such as Zmpste24) or lamin binding proteins (such as emerin). To date, more than 400 mutations in the Lamin A gene have been identified from patients. However, each mutation has a very wide range of phenotypes, and the genetic features vary such that in some cases function is gained, while in others function is lost. Fig. 2 and Table 1 show the mutations of Lamin A and the related diseases. The following section describes several mutations and their relevance to disease symptoms.

MUSCULAR DYSTROPHY

Many types of Lamin A mutations are related to muscular dystrophy. However, the tissues first affected differ from genetic mutations. Commonly called ‘muscular dystrophy’, the disease was first described in 1955 as Emery-Dreifuss muscular dystrophy (EDMD), which affects 1 in 100,000 births (24, 25). EDMD is divided into 3 groups as follows. The first group is referred to as autosomal dominant EDMD (AD-EDMD). A large portion of mutations on Lamin A is included in this group. Thus, EDMD-related Lamin A mutations are generally gain-of-function mutations. Numerous mutations have been reported as EDMD-related mutations (Table 1). The second group is referred to as autosomal recessive EDMD (AR-EDMD). Some types of Lamin A mutations that make stop codon are represented in this group (26). The third group is referred to as X-linked EDMD (XL-EDMD). This type of mutation is caused by a loss of emerin, Lamin A binding protein (25, 27). Since the emerin gene is located on the X-chromosome, XL-EDMD affects males. Although XL-EDMD causes very severe muscle dystrophy, the emerin knockout mouse model shows a healthy condition with XL-EDMD (28). This demonstrates the genetic difference between human and mouse species.

EDMD primarily affects skeletal muscles, and is detected from teenage years (26, 29). The characteristic of EDMD is a slow, progressive wasting of skeletal muscles in the shoulder girdle and distal leg muscles. The histological features of the muscles of a person affected by EDMD are various muscle fiber sizes and the mislocalization of the cell nucleus (2529). Cardiac muscle dystrophy is also observed in EDMD, which differs from dilated cardiomyopathy (CMD) in which skeletal muscles are not affected (26, 29). Thus, mutations causing EDMD seem to induce broader functional defects than CMD-related mutations. Although CDM is induced by other genes, 5 mutations on Lamin A have been reported to be related to CMD (30). In addition, Lamin A mutations also induce Limb-girdle muscular dystrophy, type 1B, and Malouf syndrome (mutations A57P and L59Rl, 3134). Interestingly, A57P and L59R mutations are also found in atypical Werner syndrome (A57P) and CDM1A (L59R). The reason why identical mutations induce different phenotypes has yet to be found. Table 1 shows the relevance of Lamin A mutations and human laminopathies.

Lipodystrophy

The clinical feature of Lipodystrophy (LD) is the reduction or loss of subcutaneous adipose tissue (35). Loss of fat has been detected from childhood or early adulthood. Two categories of LD are caused by mutation on Lamin A or related proteins: Familial partial lipodystrophy type 2 (FPLD2) and Mandibuloacral dysplasia (MAD). The main areas of the body affected by AMD are the face, neck and truck. Loss of adipose tissue can cause insulin resistance, and subsequently diabetes. The lipodystrophy-related Lamin A mutations are listed in Table 1.

Neuropathies

Duplication or overexpression of Lamin B1 induces adult-onset autosomal dominant leukodystrophy (ADLD), which is slowly progressive (36, 37). Symptoms are therefore apparent in people in their 40s and 50s. On the other hand, Lamin A mutation (R298C) can induce Charcot-Marie-Tooth (CMT) disorder (autosomal recessive CMT2A). However, the reason why the overexpression of the Lamin B1 or Lamin A mutation induces neuropathies has not yet been addressed until now.

Segmental progeroid diseases

Although mutations on Lamin A induce various types of diseases, the most interesting feature is their promotion of premature aging. Since the aging process is believed to be generated by very complicated mechanisms, it is astonishing that a single mutation on Lamin A promotes the aging process.

Hutchinson-Gilford progeria syndrome (HGPS) is a well-known aging related disease (38). HGPS is a very rare genetic disorder (1 in 20,000,000), in which all aging related features are displayed at an early stage, except cancer and neuro-degenerative diseases (3840). HGPS patients suffer from sarcopenia, lipodystrophy, diabetes, cataracts, and atherosclerosis (41). In general, patients die from cardiovascular complications in their early teenage years (41, 42). At least 90% of all HGPS cases are caused by a single base pair substitution at exon 11 of the Lamin A gene (c.1824C>T, p.G608G). Although this mutation does not change the amino acid, it generates a new splicing donor site (Fig. 2A). Thus, the product of mutation is 50 amino acid deleted (intra-deletion) abnormal Lamin A, so called progerin (Fig. 3A; 38). Since 50 amino acid sequences containing Zmpste24-cleavage sites are deleted, progerin is not processed by protease, and the farnesylated CaaX motif remains. Based on this, an attempt has previously been made to use the inhibitor of farnesyl-transferase (lonafarnib) as a treatment for HGPS, although this treatment did not show a favorable outcome (43).

Since many clinical features of HGPS resemble the physiological aging process, many researchers have expressed interest in the molecular mechanism by which progerin promotes aging (44). In fact, in healthy people, progerin expression is detected and increases with the aging process (45). Also, the cellular characteristic of HGPS, nuclear blebbing, is detected in normally aged cells (Fig. 3B), supporting the belief that the aging process induced by HGPS is a phenocopy of the physiological aging process. In addition to progerin production, several mutations have been reported to be related to HGPS.

Among the secondary laminopathy, Zmpste24 deletion is also related to segmental progeroid syndrome, Restrictive Dermopathy (RD; 46). Usually, RD patients die within a few weeks of birth due to respiratory failure (47). However, the Zmpste24−/− mouse can live longer than 6 months, although it has a small body size and aging-related phenotypes. This difference raises a new question about how the mouse model can accurately show the disease-phenotype of humans, and further indicates the difference between human and mouse systems. Along with HGPS, Werner syndrome (WS) is another well-known premature aging disease (48). Since premature aging features are displayed after puberty, it is called the ‘progeria of the adult’. Although clinical features are detected after puberty, WS shows all of the aging features, such as skin atrophy, ulcers, cataracts, type 2 diabetes mellitus, sarcoma, etc. (49, 50). Thus, WS is also believed to be a useful model for studying the physiological aging process with HGPS. Although it is a rare genetic disorder, the incidence of WS is unusually high in Japan (51). Causal mutation of WS is a loss of the WRN gene which encodes a DNA helicase, and is included in the RecQ4 family (48). Although about 80% of WS cases are caused by WRN mutation, the remaining 20% do not harbor the WRN mutation (atypical Werner syndrome: AWS; 52). Among the WS cases, a small portion (about 20%) has mutations on Lamin A (Table 1). These features suggest that some types of Lamin A mutations can disrupt the function of WRN.

MOUSE MODEL FOR LAMINOPATHIES

Mouse models are widely used to understand the physiological and pathological mechanism of human genes. The appropriate mouse model is critical in drug development for human diseases. Consequently, many trials have been performed to create a mouse model for human laminopathies. The following section summarizes the laminopathy-related mouse models.

Lamin A related knockout models (Table 2)

To address the function of Lamin A, a Lamin A/C knockout mouse has been developed by the disruption of exon 8 to exon 11 (53). The elimination of all Lamin A and Lamin C shows growth retardation and loss of body weight. Collectively, Lamin A/C deletion induces EDMD-like phenotypes. However, heterozygous mice do not show any pathological features, indicating that a single copy of LMNA is sufficient for normal function performance. In contrast to total Lamin A/C deletion, the Lamin A deleted mouse model (generated by the deletion of exon 11) does not show apparent abnormalities (56). This result implies that, at least in the mouse model, Lamin A is dispensable for normal development when Lamin C is normally expressed. In addition, a functional redundancy exists between Lamin A and Lamin C. The most interesting mouse model is LmnaLAO/LAO (22). While this mouse expresses only matured Lamin A, it is entirely normal with a nuclear defect in the fibroblast. This result leads to the same conclusion that, at least in the mouse system, prelamin A is dispensable for normal development. In fact, if Lamin A does not contain exon11 and 12, it is almost identical to Lamin C. In contrast, Zmpste24 knockout mice display progeria-like phenotypes such as growth retardation, muscular dystrophy, and short life span (6–7 months). Thus, this model has been used for the study of HGPS. However, as described above, Zmpste24 deletion evokes RD.

From the knockout mouse model of Lamin A or Zmpste24, normal function of Lamin A is required for normal development and preventing progeria features.

An emerim knockout mouse model has also been developed to study EDMD (57, 58). However, in contrast to human EDMD, complete emerin knockout does not produce EDMD phenotype. This result suggests that the regulation mechanism of Lamin A or nuclear IF between human and mouse significantly differs.

Lamin A Mutant knock-in mouse model (Table 3)

Since EDMD or lipodystrophy is an autosomal dominant pattern, to mimic these features, several types of transgenic mouse models have been proposed (5967). Curiously, AD-EDMD related mutations do not induce the EDMD phenotype in the knock-in mouse model. For example, Lmnawt/H222P mice show a phenotype undisguisable from wild type mice (62), even though this mutation induces AD-EDMD. Instead, LmnaH222P/H222P mice (homozygous mice) display EDMD phenotypes such as muscle dystrophy and lipodystrophy. We can find a similar pattern in other types of mouse model (Table 3). These differences strongly suggest a fairly significant difference between human and mouse systems.

Among the various knock-in mouse models, the LmnaG609G model has recently been intensively studied because it closely copies the human HGPS (67). Although this model shows the same limitation, LmnaG609G/G609G also shows very similar HGPS features such as obvious growth retardation, cardiovascular defects, and very short life span. Thus, using this model, intensive screening and development of new drugs for HGPS are currently being carried.

In addition to the knock-in mouse model, Lamin B1 mouse models have been generated (Table 4) since easily eliminated Lamin B1 induces an embryonic lethal phenotype (or neonatal lethal; 68). In contrast, the overexpression of Lamin B1 induces ADLD, which is consistent with human disease features (69).

CURRENT TREATMENT OF LAMINOPATHIES

Until now, an appropriate treatment for the fundamental pathogenic mechanism of laminopathies has not been suggested. Today, treatment for laminopathies is limited to relieving symptoms. Corrective surgery can be used for distorted body shape in EDMD (70) and coronary artery bypass surgery can be performed for HGPS (71). However, none of these treatments can cure the roots of these diseases.

For EDMD, the partial effect of rapamycin has been reported in a EDMD mouse model (72, 73). However, long term treatment of rapamycin can induce side effects such as lung toxicity, insulin resistance, and cataract. Thus, rapamycin is not an appropriate drug for EDMD.

Since farnesyl-residue is retained in progerin, lonafarnib (an inhibitor of farnesyl-transferase) has been used in the treatment of HGPS patients (74). Indeed, lonafarnib showed a favorable effect on nuclear morphology in a cell experiment (75). In addition, this chemical improved the disease phenotype in the Zmste24−/− mouse model (76). However, a phase II clinical trial with HGPS patients did not show any therapeutic effect (43, 77). Since lonafarnib has been developed as an anti-cancer drug, it is toxic to normal cells, rendering long-term treatmentimpossible. Indeed, long term treatment of lonafarnib induces a donut-shaped cell nucleus and defects in cell division (78). Considering the above, the treatment of lonafarnib for HGPS is not reasonable.

The co-treatment of lonafarnib and rapamycin has recently been suggested, and a clinical trial is on-going by the Progeria Research Foundation (43). However, as described above, the lonafarnib and rapamycin chemicals are not suitable for long-term treatment and they cannot correct the basic mechanism of HGSP. Antisense oligonucleotide has also been proposed for treatment of HGPS (79), and has been shown to extend the life span of a HGPS mouse model (LmnaG609G/G609G) by about 4 weeks (average life span: 16 weeks vs. 20 weeks; 80). However, until now, it has been impossible to deliver the antisense oligonucleotide to all tissues. Other approaches are currently being made to find a drug for HGPS, for example by generating a new drug for HGPS based on a novel pathological mechanism. The previous pathogenic mechanism is the accumulation of pre-lamin A and retention of farnesyl-residue. However, while Zmspte24−/− induces RD, it does not induce HGPS. This implies that progerin, a causal product of HGPS, has a unique pathological mechanism. A recent study suggested that progerin shows a very strong binding affinity with wild type Lamin A and disrupts the nuclear membrane structure (45). A new progerin-Lamin A binding inhibitor (small chemical) has thus been proposed as a candidate drug for HGPS (45). The treatment of HGPS with this chemical can extend the life span provided the antisense oligonucleotide treatment is carried out using the LmnaG609G/G609G mouse model. Moreover, an increase of the chemical dose can extend the life span up to 27 weeks (Fig. 4; 45). Thus, this chemical could be a strong candidate drug for HGPS.

CONCLUSION

In this paper, we described laminopathies and mutations. Mutations on Lamin A or related genes induce a very diverse spectrum of human diseases ranging from muscular dystrophy to progeria. In addition, we found that some mouse models are inappropriately matched for human disease due to the different systems or different roles of Lamin A among organisms. It would thus be beneficial to understand why and how Lamin A mutations on different sites or even in the same site generate different human pathologies. Until now, no clear answer on this has been presented.

Lamin A is normally processed through a multi-step process as follows. Prelamin A develops into mature Lamin A and forms the dimer. The dimerized Lamin A then develops into tetramerization by dimer-dimer interaction. Tetramerized Lamin A then forms the mesh network with Lamin A or with other linker proteins such as emerin. Therefore, each residue of Lamin A is important for each step. However, we did not know the exact mechanism of Lamin A mesh processing. In addition, Lamin A tends to hold the chromosome to retain chromosomal territory. Thus, if we know the exact molecular mechanism of Lamin A processing and function, we could develop more effective drugs for laminopathies.

Laminopathies are a group of very rare genetic disorders. However, they are involved in various types of diseases. As shown above, the progerin-mediated aging process is believed to be useful for understanding the general aging process. Similarly, laminopathy-related EDMD is possibly related to aging-induced sarcopenia or cardiac diseases. Thus, understating of the molecular mechanism of laminopathies would be useful for the investigation of other chronic diseases including diabetes and aging.

ACKNOWLEDGEMENTS

This work was supported by a 2-Year Research Grant from Pusan National University (2017–2019).

CONFLICTS OF INTEREST

The authors have no conflicting interests.

Figures
Fig. 1. Structure of LMNA gene. LMNA, encoding Lamin A/C is composed of 12 exons and the two produced proteins, Lamin A and Lamin C. Exon 1–10 are commonly used for Lamin A and C proteins. However, exon 11 and 12 are only used by Lamin A. Since the end of exon 12 encodes CaaX motif (actually CSIM), only Lamin A is a target for farnesyl-transferase. In addition, the Zmpste24 protease target sequence is located in exon 11. Thus, Farnesylated Lamin A (prelamin A) is processed into mature Lamin A. Lamin C is produced by Exon 1–10 differentially from Lamin A. However, the final exon is differentially used from lamin by alternative splicing (dark blue box in middle panel). Consequently, the six C-terminal amino acids (VSGSRR; dark blue box) are uniquely derived from Lamin A. We also showed the structural domains of Lamin A/C.
Fig. 2. Mutations on Lamin A. To date, more than 400s mutations have previously been found in Laminopathies. Mutations are widely distributed throughout the entire Lamin A gene. See for co-relationship between mutations and diseases.
Fig. 3. Lamin A processing and nuclear deformation. (A) Lamin A processing. After translation, farnesyl-transferase attaches Farnesyl-residue to CaaX motif at C-terminal end. However, protease such as Zmpste 24 cleaved the C-terminal domain. Thus, matured Lamin A does not contain Farnesyl-residue (left progression). In contrast, mutation on G609G (causal mutation of HGPS) generated an abnormal splicing donor on exon 11 and produced progerin. Since progerin still possesses CaaX motif, it is farnesylated. However, this protein no longer has the Zmpste24 cleavage site. Thus, progerin has farnesyl-residue. (B) Nuclear morphology of HGPS cells (right panel). Compared to the normal cell (left panel), the nuclear membrane of this cell showed irregularity and several knots. Green indicates Lamin A/C.
Fig. 4. Life span of HGPS mouse model. Lmna G609G/G609G mice showed a very short life span (average life span is 16 weeks). Treatment of Lamin A-progerin binding inhibitor (JH4) could extend life span up to 27 weeks. Chemicals were injected via intraperitoneal injection (i.p) with the indicated concentration (twice/week).
Tables

Relevance of Lamin A mutations and human laminopathies

Muscular dystrophy Neuropathy Lipodystrophy Segmental progeroid




CDM1A EDMD MLF MDC LGMD1B CMT2B1 FPLD2 MAD AWS HGPS
Q6X E203K Q6X G232E G449D A57P N39S R25G R298C R25W V440M A57P T10I
R25G E203G R25P L248P R453W L59R R50P Y259X R60G R471C R133L S143E
R25W L215P R25G R249Q L454P R249W E358K R62G R527C L140R S143F
L59R R225X E33G R249W N456I L302P R377H ΔK208 R527H D300N E145K
R60G Y267C L35V F260L N456K E358K R377L D230N A529V Q656Q R471C
E82K E317K N39S Y267C D461Y L380S R399C G456D R527C
L85R A347K A43T S268P W467R R453P Y481H R482W T528M
R89L R349L Y45C L271P I469T R455P R482Q M540T
K97E Q355X R50S Q294P W520S N456D R482L K542N
S143P R399C I63S S295P R527P P485R E578V
E161K R435C I63N S303P T528K K486N V607V
R190W R541C E65G R336Q T528R S573L G608S
D192G R541S R89C R343Q L529P R582H G608G
N195K S573L R133P E358K L530P R584H T623S
R644C L140P E361K R541H
T150P M371K R541S
R189P R377L R541P
R190Q R386K G602S
R196S R401C R624H
H222P V442A
H222Y D446V

CDM1A: Cardiomyopathy, dilated, 1A, EDMD: Emery-Dreifuss Muscular dystrophy, MLF: Malouf syndrome, MDC: Muscular dystrophy, congenital, LGMD1B: Muscular dystrophy, limb-gardle, type 1B, CMT1B1: Charcot-Marie-Tooth disease, type 2B1, FDLD2: Lipodystrophy, familial partial, 2, MAD: Mandibuloacral dysplasia lipodystrophy, AWS: Atypical Werner syndrome, HGPS: Hutchinson-Gilford progeria syndrome.


List of knockout mouse model of Lamin A or related proteins

Abbreviation Mutation Homozygous Mouse Phenotype Heterozygous Mouse Phenotype Disease in Human Ref
Lmna−/− Destruction of exons 8 to part of 11 by using insertion of neomycin resistant cassette Growth rate retardation. Body weight loss. Emery-Dreifuss muscular dystrophy (EDMD)-like phenotype No apparent abnormalities Not described 53
Zmpste24−/− Deletion of exons 2, 3 using insertion of neomycin resistant cassette Growth rate reduction. Pre-mature aging No apparent abnormalities Not described 54
LmnaGT −/− A promoter trap insertion into intron 2 resulting in a Lamin A-pgeo fusion allele Cardiac hypertrophy causing functional failure. Skeletal muscle hypotrophy. No apparent abnormalities Not described 55
LmnaLCO/LCO Deletion of last 150 nucleotides of exon 11 and deletion of intron 11 No apparent abnormalities No apparent abnormalities Not described 56
LmnaLAO/LAO Mature Lamin A only No apparent abnormalities No apparent abnormalities Not described 22
EDM−/− Emerin deletion No apparent abnormalities (slight retardation on muscle regeneration) No apparent abnormalities EDMD 57,58

List of point mutant mouse model for laminopathies

Abbreviation Mutation Homozygous Mouse Phenotype Heterozygous Mouse Phenotype Disease in Human Ref
ΔK32 Deletion of K32 in the N-terminal domain of lamins A/C Kinked tail. Growth retardation. Stagnation in weight gain. Congenital muscular dystrophy. Indistinguishable phenotype Congenital muscular dystrophy. 59
Disheveled hair and ear (Dhe) Sponteneous L52R mutation Defect in bone mineralization, and low collagen expression causing abnormal morphology of skull, jaws, and ears. Low bone mineral density. Defect in bone mineralization, and low collagen expression causing abnormal morphology of skull, jaws, and ears. Low bone mineral density. Not described 60
N195K Missense mutaiton Weight loss. Shortened lifespan. Dilated cardiomyopathy (DCM)-like phenotype Not described Dilated cardiomyopathy (DCM) 61
H222P Missense mutaiton Indistinguishable phenotype during sexual maturity stage. Weight loss and reduced growth rate in adult stages. Cardiac dysfunction. Skeletal muscle dystrophy. Lipodystrophy. Indistinguishable phenotype Not described 62
M371K Missense mutaiton Cardiac pathology (I0ncreased cytoplasmic eosinophilia of cardiomyocytes, focal edema, fragmented cardiomyofibrils and pyknotic-appearing nuclei) Not described Not described 63
R482Q Missense mutaiton Not described Familial partial lipodystrophy of the Dunnigan type (FPLD2) Familial partial lipodystrophy of the Dunnigan type (FPLD2). No homozygous patients have been identified. 64
L530P Missense mutaiton Progeroid phenotype. Growth retardation. Indistinguishable phenotype Autosomal dominant form of Emery Dreifuss muscular dystrophy (AD-EDMD) 65
G608G Mouse G606G base change using BAC system Progeroid phenotype. Growth retardation. Indistinguishable phenotype Hutchinson–Gilford progeria syndrome (HGPS) 66
G609G Insertion of G609G in exon 11 Hutchinson–Gilford progeria syndrome (HGPS) Hutchinson–Gilford progeria syndrome (HGPS) Hutchinson–Gilford progeria syndrome (HGPS) 67

Mouse model of Lamin B mutations

Abbreviation Mutation Homozygous Mouse Phenotype Heterozygous Mouse Phenotype Disease in Human Ref
Lamin B1 Δ/Δ Portion of the rod domain and the entire carboxyl-terminal domain are replaced by gene trap insertion Embryonic lethal, reduced embryo size and shows abnormal embryo shape. Abnormal lung development and bone ossification in embryo development No apparent abnormalities Not described 68
Lamin B1 BAC Overexpresion of Lamin B1 using BAC insertion Autosomal-dominant leukodystrophy (ADLD). Aberrant myelin formation, axonal degeneration, and demyelination causing cognitive and motor deficits. No apparent abnormalities Autosomal-domina nt leukodystrophy (ADLD) 69

References
  1. McKenna T, Baek JH, and Eriksson M (2013) Laminopathies. Genetic Disorders chapter 2, 28-64.
    CrossRef
  2. Cronshaw JM, Kruchinsky AN, Zhang W, Chait BT, and Matunis MJ (2002) Proteomic analysis of the mammalian nuclear pore complex. J Cell Biol 158, 915-927.
    Pubmed KoreaMed CrossRef
  3. Aebi U, Cohn J, Buhle L, and Gerace L (1986) The nuclear lamina is a meshwork of intermediate-type filaments. Nature 323, 560-564.
    Pubmed CrossRef
  4. Gruenbaum Y, and Foisner R (2015) Lamins: Nuclear intermediate filament proteins with fundamental functions in nuclear mechanics and genome regulation. Annu Rev Biochem 84, 131-164.
    Pubmed CrossRef
  5. Clements L, Manilal S, Love DR, and Morris GE (2000) Direct interaction between emerin and lamin A. Biochem Biophys Res Commun 267, 709-714.
    Pubmed CrossRef
  6. Zastrow MS, Vlcek S, and Wilson KL (2004) Proteins that bind A-type lamins: integrating isolated clues. J Cell Sci 117, 979-987.
    Pubmed CrossRef
  7. Salpingidou G, Smertenko A, Hausmanowa-Petrucewicz I, Hussey PJ, and Hutchison CJ (2007) A novel role for the nuclear membrane protein emerin in association of the centrosome to the outer nuclear membrane. J Cell Biol 178, 897-904.
    Pubmed KoreaMed CrossRef
  8. Chang W, Folker ES, Worman HJ, and Gundersen GG (2013) Emerin organizes actin flow for nuclear movement and centrosome orientation in migrating fibroblasts. Mol Biol Cell 24, 3869-3880.
    Pubmed KoreaMed CrossRef
  9. Constantinescu D, Gray HL, Sammak PJ, Schatten GP, and Csoka AB (2006) Lamin A/C expression is a marker of mouse and human embryonic stem cell differentiation. Stem Cells 24, 177-185.
    Pubmed CrossRef
  10. Röber RA, Weber K, and Osborn M (1989) Differential timing of nuclear lamin A/C expression in the various organs of the mouse embryo and the young animal: a developmental study. Development 105, 365-378.
    Pubmed
  11. Briand N, and Collas P (2018) Laminopathy-causing lamin A mutations reconfigure lamina-associated domains and local spatial chromatin conformation. Nucleus 9, 216-226.
    Pubmed KoreaMed CrossRef
  12. Chojnowski A, Ong PF, and Dreesen O (2015) Nuclear lamina remodeling and its implications for human disease. Cell Tissue Res 360, 621-631.
    Pubmed CrossRef
  13. Worman HJ (2012) Nuclear lamins and laminopathies. J Pathol 226, 316-325.
    Pubmed CrossRef
  14. Ben Yaou R, Muchir A, and Arimura T (2005) Genetics of laminopathies. Novartis Found Symp 264, 81-90.
    Pubmed
  15. Hollstein M, Sidransky D, Vogelstein B, and Harris CC (1991) p53 mutations in human cancers. Science 253, 49-53.
    Pubmed CrossRef
  16. Fisher D, and Chaudhary N (1986) cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Ntl Acad Sci U S A 83, 6450-6454.
    Pubmed KoreaMed CrossRef
  17. Lin F, and Worman HJ (1993) Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem 268, 16321-16326.
    Pubmed
  18. Barrowman J, Hamblet C, Geoge CM, and Michaelis S (2008) Analysis of prelamin A biogenesis reveals the nucleus to be a CaaX processing compartment. Mol Biol Cell 19, 5398-5408.
    Pubmed KoreaMed CrossRef
  19. Barrowman J, Hamblet C, Kane MS, and Michaelis S (2012) Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24. PLoS One 7, e32120.
    Pubmed KoreaMed CrossRef
  20. Landires I, Pascale JM, and Motta J (2007) The position of the mutation within the LMNA gene determines the type and extent of tissue involvement in laminopathies. Clin Genet 71, 592-593.
    Pubmed CrossRef
  21. Broers JLV, Ramaekers FCS, Bonne G, Yaou RB, and Hutchison CJ (2006) Nuclear lamins: laminopathies and their role in premature ageing. Physiol Rev 86, 967-1008.
    Pubmed CrossRef
  22. Coffinier C, Jung HJ, and Li Z (2010) Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J Biol Chem 285, 20818-20826.
    Pubmed KoreaMed CrossRef
  23. Kitten GT, and Nigg EA (1991) The CaaX motif is required for isoprenylation, carboxyl methylation, and nuclear membrane association of lamin B2. J Cell Biol 113, 13-23.
    Pubmed KoreaMed CrossRef
  24. Emery AE, and Dreifuss FE (1966) Unusual type of benign x-linked muscular dystrophy. J Neurol Neurosurg Psychiatry 29, 338-342.
    Pubmed KoreaMed CrossRef
  25. Muchir A, and Worman HJ (2007) Emery-Dreifuss muscular dystrophy. Curr Neurol Neurosci Rep 7, 78-83.
    Pubmed CrossRef
  26. Bonne G, Mercuri E, and Muchir A (2000) Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol 48, 170-180.
    Pubmed CrossRef
  27. Helbling-Leclerc A, Bonne G, and Schwartz K (2002) Emery-Dreifuss muscular dystrophy. Eur J Hum Genet 10, 157-161.
    Pubmed CrossRef
  28. Stewart CL, Kozlov S, Fong LG, and Young SG (2007) Mouse models of the laminopathies. Exp Cell Res 313, 2144-2156.
    Pubmed KoreaMed CrossRef
  29. Canki-Klain N, Récan D, and Milicić D (2000) Clinical variability and molecular diagnosis in a four-generation family with X-linked Emery-Dreifuss muscular dystrophy. Croat Med J 41, 389-395.
    Pubmed
  30. Fatkin D, MacRae C, and Sasaki T (1999) Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341, 1715-1724.
    Pubmed CrossRef
  31. Muchir A, Bonne G, and van der Kooi AJ (2000) Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances. Hum Mol Genet 9, 1453-1459.
    Pubmed CrossRef
  32. Yuan WL, Huang CY, and Wang JF (2009) R25G mutation in exon 1 of LMNA gene is associated with dilated cardiomyopathy and limb-girdle muscular dystrophy 1B. Chin Med J 122, 2840-2845.
    Pubmed
  33. McPherson E, Turner L, Zador I, Reynolds K, Macgregor D, and Giampietro PF (2009) Ovarian failure and dilated cardiomyopathy due to a novel lamin mutation. Am J Med Genet 149A, 567-572.
    Pubmed CrossRef
  34. Garg A, Subramanyam L, and Agarwal AK (2009) Atypical progeroid syndrome due to heterozygous missense LMNA mutations. J Clin Endocrinol Metab 94, 4971-1983.
    Pubmed KoreaMed CrossRef
  35. Shackleton S, Lloyd DJ, and Jackson SN (2000) LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 24, 153-156.
    Pubmed CrossRef
  36. Padiath QS, Saigoh K, and Schiffmann R (2006) Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet 38, 1114-1123.
    Pubmed CrossRef
  37. Schuster J, Sundblom J, and Thuresson AC (2011) Genomic duplications mediate overexpression of lamin B1 in adult-onset autosomal dominant leukodystrophy with autonomic symptoms. Neurogenetics 12, 65-72.
    Pubmed CrossRef
  38. Eriksson M, Brown WT, and Gordon LB (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423, 293-298.
    Pubmed CrossRef
  39. Rodríguez JI, Pérez-Alonso P, Funes R, and Pérez-Rodríguez J (1999) Lethal neonatal Hutchinson-Gilford progeria syndrome. Am J Med Genet 82, 242-248.
    Pubmed CrossRef
  40. Gillar PJ, Kaye CI, and McCourt JW (1991) Progressive early dermatologic changes in Hutchinson-Gilford progeria syndrome. Pediatr Dermatol 8, 199-206.
    Pubmed CrossRef
  41. Merideth MA, Gordon LB, and Clauss S (2008) Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358, 592-604.
    Pubmed KoreaMed CrossRef
  42. Salamat M, Dhar PK, Neagu DL, and Lyon JB (2010) Aortic calcification in a patient with Hutchinson-Gilford progeria syndrome. Pediatr Cardiol 31, 925-926.
    Pubmed CrossRef
  43. Gordon LB, Kleinman ME, and Massaro J (2016) Clinical trial of the protein farnesylation inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in children with Hutchinson-Gilford progeria syndrome. Circulation 134, 114-125.
    Pubmed KoreaMed CrossRef
  44. Dechat T, Shimi T, and Adam SA (2007) Alterations in mitosis and cell cycle progression caused by a mutant lamin A known to accelerate human aging. Proc Natl Acad Sci U S A 104, 4955-4960.
    Pubmed KoreaMed CrossRef
  45. Lee SJ, Jung YS, and Yoon MH (2016) Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype. J Clin Invest 126, 3879-3893.
    Pubmed KoreaMed CrossRef
  46. Smigiel R, Jakubial A, and Esteves-Vieira V (2010) Novel frameshifting mutations of the ZMPSTE24 gene in two siblings affected with restrictive dermopathy and review of the mutations described in the literature. Am J Med Genet 152A, 447-452.
    Pubmed CrossRef
  47. Mok Q, Curley R, Tolmie J, and Marsden R (1990) Restrictive dermopathy: a report of three cases. J Met Genet 27, 315-319.
    Pubmed KoreaMed CrossRef
  48. Yu CE, Oshima J, and Fu YH (1996) Positional cloning of the Werner’s syndrome gene. Science 272, 258-262.
    Pubmed CrossRef
  49. Hisama FM, Lessel D, and Leistritz D (2011) Coronary artery disease in a Werner syndrome-like form of progeria characterized by low levels of progerin, a splice variant of lamin A. Am J Med Genet 155A, 3002-3006.
    Pubmed KoreaMed CrossRef
  50. Hisama FM, Kubisch C, Martin GM, and Oshima J (2012) Clinical utility gene card for: Werner syndrome. Eur J Hum Genet 20, 1-3.
    Pubmed KoreaMed CrossRef
  51. Goto M, Horiuchi Y, Tanimoto K, Ishii T, and Nakashima H (1978) Werner’s syndrome: analysis of 15 cases with a review of the Japanese literature. J Am Geriatr Soc 26, 341-347.
    Pubmed CrossRef
  52. Chen L, Lee L, and Kudlow BA (2003) LMNA mutations in atypical Werner’s syndrome. Lancet 362, 440-445.
    Pubmed CrossRef
  53. Sullivan T, Escalante-Alcalde D, and Bhatt H (1999) Loss of A-type lamin expression compromise nuclear envelope integrity leading to muscular dystrophy. J Cell Biol 147, 913-920.
    Pubmed KoreaMed CrossRef
  54. Pendás AM, Zhou Z, and Candiñanos J (2002) Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 31, 94-99.
    Pubmed CrossRef
  55. Kubben N, Voncken JW, and Konings G (2011) Post-natal myogenic and adipogenic developmental: defects and metabolic impairment upon loss of A-type lamins. Nucleus 2, 195-207.
    Pubmed KoreaMed CrossRef
  56. Fong LG, Ng JK, and Lammerding J (2006) Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest 116, 743-752.
    Pubmed KoreaMed CrossRef
  57. Melcon G, Kozlov S, and Cutler DA (2006) Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and Myo D pathways during muscle regeneration. Hum Mol Genet 15, 637-651.
    Pubmed CrossRef
  58. Ozawa R, Hayashi YK, and Ogawa M (2006) Emerin-lacking mice show minimal motor and cardiac dysfunctions with nuclear-associated vacuoles. Am J Pathol 168, 907-917.
    Pubmed KoreaMed CrossRef
  59. Pilat U, Dechat T, and Bertrand AT (2013) The muscle dystrophy-causing ΔK32 lamin A/C mutant does not impair the functions of the nucleoplasmic lamin A/C-LAP2α complex in mice. J Cell Sci 126, 1753-1762.
    Pubmed KoreaMed CrossRef
  60. Odgren PR, Pratt CH, and Mackay CA (2010) Disheveled hair and ear (Dhe), a spontaneous mouse Lmna mutation modeling human laminopathies. PLoS One 5, e9959.
    Pubmed KoreaMed CrossRef
  61. Mounkes LC, Kozlov SV, Rottman JN, and Stewart CL (2005) Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice. Hum Mol Genet 14, 2167-2180.
    Pubmed CrossRef
  62. Arimura T, Helbling-Leclerc A, and Massart C (2005) Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum Mol Genet 14, 155-169.
    Pubmed CrossRef
  63. Wang Y, Herron AJ, and Worman HJ (2006) Pathology and nuclear abnormalities in hearts of transgenic mice expressing M371K lamin A encoded by an LMNA mutation causing Emery-Dreifuss muscular dystrophy. Hum Mol Genet 15, 2479-2489.
    Pubmed CrossRef
  64. Wojtanik KM, Edgemon K, and Viswanadha S (2009) The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation. J Lipid Res 50, 1068-1079.
    Pubmed KoreaMed CrossRef
  65. Mounkes LC, Kozlov S, Hernandez L, Sullivan T, and Stewart CL (2003) A progeroid syndrome in mice is caused by defects in A-type lamins. Nature 423, 298-301.
    Pubmed CrossRef
  66. Varga R, Eriksson M, and Erdos MR (2006) Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 103, 3250-3255.
    Pubmed KoreaMed CrossRef
  67. Osorio FG, Navarro CL, and Cadiñanos J (2011) Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med 3, 106ra107.
    Pubmed CrossRef
  68. Vergnes L, Péterfy M, Bergo MO, Young SG, and Reue K (2004) Lamin B1 is required for mouse development and nuclear integrity. Proc Natl Acad Sci U S A 101, 10428-10433.
    Pubmed KoreaMed CrossRef
  69. Heng MY, Lin ST, and Verret L (2013) Lamin B1 mediates cell-autonomous neuropathology in a leukodystrophy mouse model. J Clin Invest 123, 2719-2729.
    Pubmed KoreaMed CrossRef
  70. Ambrosi P, Mouly-Bandini A, Attarian S, and Habib G (2009) Heart transplantation in 7 patients form a single family with limb-girdle muscular dystrophy caused by lamin A/C mutation. Int J Cardiol 137, e75-76.
    Pubmed CrossRef
  71. Dyck JD, David TE, Burke B, Webb GD, Henderson MA, and Fowler RS (1987) Management of coronary artery disease in Hutchinson-Gilford syndrome. J Pediatr 111, 407-410.
    Pubmed CrossRef
  72. Ramos FJ, Chen SC, and Garelick MG (2012) Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescue cardiac and skeletal muscle function, and extends survival. Sci Transl Med 4, 144ra103.
    Pubmed KoreaMed CrossRef
  73. Choi JC, Muchir A, Wu W, and Iwata S (2012) Temsirolimus activates autophagy and ameliorates cardiomyopathy caused by lamin A/C mutation. Sci Transl Med 4, 144ra102.
    Pubmed KoreaMed CrossRef
  74. Kieran MW, Gordon L, and Kleinman M (2007) New approaches to progeria. Pediatrics 120, 834-841.
    Pubmed CrossRef
  75. Capell B, Erdos M, Medigan J, and Fiordalisi J (2005) Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Pro Natl Acad Sci U S A 102, 12879-12884.
    Pubmed KoreaMed CrossRef
  76. Fong L, Frost D, Meta M, Qiao X, and Yang S (2006) A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311, 1621-1623.
    Pubmed CrossRef
  77. Gordon LB, Kleinman ME, and Miller DT (2012) Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 109, 16666-16671.
    Pubmed KoreaMed CrossRef
  78. Verstraeten VL, Peckham LA, and Olive M (2011) Protein farnesylation inhibitors cause donut-shaped cell nuclei attributable to a centrosome separation defect. Proc Natl Acad Sci U S A 108, 4997-5002.
    Pubmed KoreaMed CrossRef
  79. Scaffidi P (2006) Lamin A-dependent nuclear defects in human aging. Science 312, 1059-1063.
    Pubmed KoreaMed CrossRef
  80. Osorio FG, Navarro CL, and Cadinanos J (2011) Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med 3, 106ra107.
    Pubmed CrossRef


This Article


Cited By Articles

Funding Information

Services
Social Network Service

e-submission

Archives